Clinical trial
A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
NCT00000751 is registered in ClinicalTrials.gov with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- August 31, 2007
- Enrollment
- 1,600
- Sites
- 51
Conditions
As the registry lists them; a condition with its own page is linked.
hiv infections, pregnancy